Advertisement
Screener

Definium Therapeutics, Inc. (DFTX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.8 / 5 stars · 68/120 Roast Me

Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-02-26

  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-09-30 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-06-30 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-09-30 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
10-K · filed 2026-02-26
2024-12-310.00%
10-K · filed 2026-02-26
2023-12-310.00%
10-K · filed 2025-03-06
2022-12-310.00%
10-K · filed 2024-02-28
2022-09-300.00%
10-Q · filed 2022-11-10
0.00%
10-Q · filed 2022-11-10
2022-06-300.00%
10-Q · filed 2022-08-11
0.00%
10-Q · filed 2022-08-11
2022-03-310.00%
10-Q · filed 2022-05-16
2021-12-310.00%
10-K · filed 2023-03-09
2021-09-300.00%
10-Q · filed 2022-11-10
0.00%
10-Q · filed 2022-11-10
2021-06-300.00%
10-Q · filed 2022-08-11
0.00%
10-Q · filed 2022-08-11
2021-03-310.00%
10-Q · filed 2022-05-16
2020-12-310.00%
10-K · filed 2022-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cronos Group Inc. (CRON)$1.223B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B